Harrow Health, Inc. (HROW) Key Statistics & Metrics

Harrow Health, Inc. (HROW) has an ST Score of 39.4 out of 100, an overall grade of C. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on HROW is Buy based on 10 analyst ratings. Our own ST Score grades it C (39.4/100). This is data, not investment advice — always do your own research.

Harrow Health, Inc. (HROW) earns a valuation grade of D, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Harrow Health, Inc. (HROW) earns a growth grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Harrow Health, Inc. (HROW) earns a profitability grade of B-, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Harrow Health, Inc. (HROW) earns a financial strength grade of D+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Harrow Health, Inc. (HROW) is $66.50 from 10 analysts, which is +1.0% versus the recent price of $33.92.

Harrow Health, Inc. (HROW) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.